Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury
ConditionAcute Kidney Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversität Münster
About this trial
This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Critically ill patients with moderate or severe AKI (KDIGO stage 2 / 3)
Requirement of vasopressors or mechanical ventilation
Age ≥ 18 years
Informed consent
Disqualifiers
Chronic kidney disease (CKD) with a glomerular filtration rate < 20ml/min
Chronic dialysis dependency
History of renal transplantation
Permanent ligation of the renal arteries
Trial population
Critically ill patients (intensive care unit of the participating study sites)
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Nephroprotective measures
Procedure/SurgeryDue to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
Treatment groups
257 Participants
are divided into 1 treatment groupGroup A: Critically ill patients1 intervention
Trial outcomes
Primary outcomes
1
Rate of patients in whom "Kidney Disease: Improving Global Outcomes (KDIGO)" guideline recommendations are successfully implemented for 48 hours, following the onset of moderate/ severe AKI (defined by KDIGO criteria)
Time frame
60 hours after onset of moderate/severe AKISecondary outcomes
1
Severity of Acute Kidney Injury
Severity of AKI (worst Acute Kidney Injury (AKI) stage according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria, with stage 1 being the least and stage 3 being the most severe stage)
Time frame
within 72 hours after diagnosis2
Duration of AKI (Acute Kidney Injury)
transient AKI (\< 48 hours), persistent AKI (48 hours - 7 days) or acute kidney disease (AKD) (\> 7 days)
Time frame
from onset of AKI until follow-up day 30Other outcomes
1
Number of participants with recovery of baseline renal function
recovery of baseline renal function measured by estimated glomerular filtration rate (eGFR) at hospital discharge
Time frame
hospital discharge (up to 30 days)2
Number of Participants with need for renal replacement therapy
defined as whether or not any kind of renal replacement therapy became necessary at any point
Time frame
within 30 days of AKI onset3
Free-days of mechanical ventilation
Time frame
within 30 days of AKI onset4
Length of hospital stay
Time frame
at hospital discharge (up to 30 days)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov